Cellzome Announces Achievement of First Milestone in Inflammation Alliance with GlaxoSmithKline
News Dec 11, 2008
Cellzome Inc. announced that it has successfully achieved the first milestone in the strategic alliance with GlaxoSmithKline (GSK) established earlier this year, triggering payment of an undisclosed amount.
In September this year, Cellzome and GSK announced the signing of a worldwide strategic alliance to apply Cellzome’s drug discovery and development capabilities and its proprietary Kinobeads™ technology to identify, develop and market novel, kinase-targeted therapeutics to treat inflammatory diseases. GSK has exclusive options to license drug candidates from Cellzome’s kinase programs directed against seven targets.
Cellzome will develop these programs to clinical proof of concept, unless GSK elects to exercise its option earlier, and Cellzome is eligible to receive success-based milestones from GSK as product candidates are advanced. The milestone is the first of such payments under the agreement.
Tim Edwards, CEO of Cellzome, said: “We are making excellent progress on the programs optioned to GSK. The achievement of this first milestone so soon after the start of our collaboration is evidence of this and bears testimony to the power of our Kinobeads™ technology and the quality of our scientists. We look forward to continued success in this alliance.”
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019